4D pharma Announces Passing of Chief Financial Officer John Beck
July 26 2021 - 7:00AM
Business Wire
4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical
company leading the development of Live Biotherapeutic products
(LBPs), a novel class of drug derived from the microbiome,
announces with great sadness that John Beck, Chief Financial
Officer of 4D pharma, has passed away.
“We are deeply saddened by John’s passing. The entire 4D pharma
community mourns this loss and, on behalf of our Board of Directors
and employees, we extend our sincerest condolences to his family,”
said Duncan Peyton, Chief Executive Officer of 4D pharma. “John’s
30 years of experience in the financial and biopharmaceutical
industries were invaluable to us in his role as Chief Financial
Officer, and his vision for the future of 4D pharma was already
well on its way to being realized. We grieve this loss and will
carry his legacy forward in this next chapter of 4D pharma
continued growth and progress.”
4D pharma will continue to be actively led by its current
management team and Board of Directors and succession planning is
underway.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx®, that rationally identifies Live Biotherapeutics based on
a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has five clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome
(IBS) which has completed a successful Phase II trial.
Preclinical-stage programs include candidates for CNS disease such
as Parkinson's disease and other neurodegenerative conditions. The
Company has a research collaboration with MSD, a tradename of Merck
& Co., Inc., Kenilworth, NJ, USA, to discover and develop Live
Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210726005352/en/
4D pharma Investor Relations: ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496
3000 Philip Davies / Iqra Amin / James Fischer (Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500 Dominic Wilson / Phil Walker
Stern Investor Relations, Inc. +1-212-362-1200 Julie Seidel
Julie.seidel@sternir.com
Image Box Communications +44 (0)20 8943 4685 Neil Hunter /
Michelle Boxall neil@ibcomms.agency / michelle@ibcomms.agency
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024